AMBS PIPELINE
AMBS has over 138 patents, licenses, options to license/patent assays in its product pipeline, and they hold rights to other intellectual property as well.
MANF: AMBS has obtained worldwide rights to MANF covering all neurological indications. They include but are not limited to:
1). Parkinson's Disease (PD)
2). Amyotrophic Lateral Sclerosis (ALS) - Lou Gehrig's Disease -
3). Ischemic Heart Disease
4). Alzheimer's Disease (AD)
5). Huntington's Disease
6). Traumatic Brain Injury/ Chronic Traumatic Encephalopathy (TBI/CTE)
http://ir.amarantus.com/company-news/detail/9...-discovery
MANF: AMBS has entered into a license agreement with University of Miami Bascom-Palmer Eye Institute (ranked #1 in the U.S.) giving them rights to assays for the following indications:
7). Retinitis Pigmentosa (RP); and,
. other Inherited Retinal Disorders
9). Age related macular degeration
10). Glaucoma
11). Sporadic Retinal Disorders
12). Other degenerative disorders and retinal injury
From the second paragraph.
http://ir.amarantus.com/company-news/detail/1...-disorders
MANF: AMBS has a license agreement with Washington University for assays covering the following indications:
13). Wolfram's Syndrome
14). Diabetes Type-1
The third paragraph.
http://ir.amarantus.com/company-news/detail/1...f-medicine
On Dec. 26, 2012, AMBS obtained the entire Power3 Medical Products Intellectual Property (IP) portfolio covering 20 patents and all other IP rights:
15-34).
http://ir.amarantus.com/company-news/detail/4...-from-powe
Lympro: On 5-5-14 AMBS obtained patent rights for LP-002 for the following indications:
35). Alzheimer's Disease (AD)
36) TBI/CTE
http://ir.amarantus.com/company-news/detail/1...rs-disease
Eltoprazine: AMBS in-licenses Eltoprazine on 1-14-14. Elto covers two indications:
37). Parkinson's Disease Levodopa Induced Dyskinesia (PD-LID)
38). Attention Deficit Hyperactivity Disorder (ADHD)
http://ir.amarantus.com/company-news/detail/1...-discovery
Georgtown Acquisitions: AMBS has a option to liscense agreement with Georgetown University for patent rights to a suite of Blood Based Biomarker test for six assays:
39). Lipidomics Assay
40). Exosoms Assay
41-45). Four additional Assays
From the second paragraph.
http://ir.amarantus.com/company-news/detail/1...rs-disease
Engineered Skin Substitute (ESS)
On Nov.17, 2014, AMBS announced it had obtained all rights to ESS from Lonza-Walkerville:
46). ESS for type 3 and 4 intractable sever burns
http://ir.amarantus.com/company-news/detail/1...from-lonza
DioGenix Acquisitions: On 1-12-15 AMBS announced it had merge DioGenix into AMBS and has obtained all IP rights of DioGenix
47). MSPrecise Diagnostic for Multiple Sclerosis (MS)
48). Neurosarcoid Diagnostic Assay
49). Neuromeylitis optica Diagnostic Assay
50). Para neoplastic Disease Diagnostic Assay
51). Amyotrophic Lateral Sclerosis (ALS) Diognostic Assay
From the second paragraph.
http://ir.amarantus.com/company-news/detail/1...y-diogenix
Phenogaurd Cell Lines (87)
52-138) Phenogaurd
AMBS announced on Mar. 6, 2014, it has entered into an exclusive license with University of Massachusetts for all rights for MANF in Antibiotic Induced Ototoxicity: (actual number of licenses not mentioned, however, ototoxicity covers over 120 drugs and pharmacological agents)
http://medical-dictionary.thefreedictionary.com/ototoxicity
http://ir.amarantus.com/company-news/detail/1...totoxicity
*note: AMBS has several assays covering the same indications: two diagnostic for ALS, and a therapeutic as well..etc.
It appears to me that over the past two and a half years AMBS has been building a world class company with a massive pipeline. In that same time period they have gone from a company that only had office furniture, a gift of rented office space from the Michael J. fox Foundation (MJFF), and a portfolio with nothing more than MANF and the Phenogaurd cell lines; into a company worth ~50 million dollars and more than 138 assays in its pipeline, and other intellectual property as well.
It has come at the price of stock dilution, will there be future dilution?...yes, most certainly, but it will not be as severe as in the past, and the impact of future dilution will likely be offset by other funding sources. Perhaps by the Grow New Jersey tax credit, Grants from the DoD for ESS, The MJFF (Elto, Neuropro, MANF), or perhaps more favorable financing with the release of catalyst (GC said he has the CED data but cannot release it at this time).
I feel the future has tremendous potential for AMBS, so I hold long and strong!
Warmest regards,
Hoosier
This post should not be considered investment advise. I am not recommending to buy, sell, or hold this security, or any other. This post should be only considered my observations how AMBS has evolved over the past two and a half years.
GLTA
AMBS has over 138 patents, licenses, options to license/patent assays in its product pipeline, and they hold rights to other intellectual property as well.
MANF: AMBS has obtained worldwide rights to MANF covering all neurological indications. They include but are not limited to:
1). Parkinson's Disease (PD)
2). Amyotrophic Lateral Sclerosis (ALS) - Lou Gehrig's Disease -
3). Ischemic Heart Disease
4). Alzheimer's Disease (AD)
5). Huntington's Disease
6). Traumatic Brain Injury/ Chronic Traumatic Encephalopathy (TBI/CTE)
http://ir.amarantus.com/company-news/detail/9...-discovery
MANF: AMBS has entered into a license agreement with University of Miami Bascom-Palmer Eye Institute (ranked #1 in the U.S.) giving them rights to assays for the following indications:
7). Retinitis Pigmentosa (RP); and,
. other Inherited Retinal Disorders 9). Age related macular degeration
10). Glaucoma
11). Sporadic Retinal Disorders
12). Other degenerative disorders and retinal injury
From the second paragraph.
http://ir.amarantus.com/company-news/detail/1...-disorders
MANF: AMBS has a license agreement with Washington University for assays covering the following indications:
13). Wolfram's Syndrome
14). Diabetes Type-1
The third paragraph.
http://ir.amarantus.com/company-news/detail/1...f-medicine
On Dec. 26, 2012, AMBS obtained the entire Power3 Medical Products Intellectual Property (IP) portfolio covering 20 patents and all other IP rights:
15-34).
Quote:12/802,630 – Diagnosis of Parkinson's Disease
13/118,175 – Assays for diagnosis and therapeutics...ALS and Parkinson's Disease
12/069,807 – 47 Protein Biomarkers for Neurodegenerative Diseases
12/804,868 – Assays for Amyotrophic Lateral Sclerosis (ALS) and ALS-like disorders
13/153,669 – Diagnosis of Alzheimer's Disease
As part of the transaction, Amarantus took ownership of 20 pending patent applications covering a variety of biomarkers and assays related to the treatment of various diseases including Parkinson's, Alzheimer's, and ALS, as well as patent applications related to Breast Cancer, neuromuscular disease and Chronic Myelogenous Leukemia (CML).
http://ir.amarantus.com/company-news/detail/4...-from-powe
Lympro: On 5-5-14 AMBS obtained patent rights for LP-002 for the following indications:
35). Alzheimer's Disease (AD)
36) TBI/CTE
http://ir.amarantus.com/company-news/detail/1...rs-disease
Eltoprazine: AMBS in-licenses Eltoprazine on 1-14-14. Elto covers two indications:
37). Parkinson's Disease Levodopa Induced Dyskinesia (PD-LID)
38). Attention Deficit Hyperactivity Disorder (ADHD)
http://ir.amarantus.com/company-news/detail/1...-discovery
Georgtown Acquisitions: AMBS has a option to liscense agreement with Georgetown University for patent rights to a suite of Blood Based Biomarker test for six assays:
39). Lipidomics Assay
40). Exosoms Assay
41-45). Four additional Assays
From the second paragraph.
http://ir.amarantus.com/company-news/detail/1...rs-disease
Engineered Skin Substitute (ESS)
On Nov.17, 2014, AMBS announced it had obtained all rights to ESS from Lonza-Walkerville:
46). ESS for type 3 and 4 intractable sever burns
http://ir.amarantus.com/company-news/detail/1...from-lonza
DioGenix Acquisitions: On 1-12-15 AMBS announced it had merge DioGenix into AMBS and has obtained all IP rights of DioGenix
47). MSPrecise Diagnostic for Multiple Sclerosis (MS)
48). Neurosarcoid Diagnostic Assay
49). Neuromeylitis optica Diagnostic Assay
50). Para neoplastic Disease Diagnostic Assay
51). Amyotrophic Lateral Sclerosis (ALS) Diognostic Assay
From the second paragraph.
http://ir.amarantus.com/company-news/detail/1...y-diogenix
Phenogaurd Cell Lines (87)
52-138) Phenogaurd
AMBS announced on Mar. 6, 2014, it has entered into an exclusive license with University of Massachusetts for all rights for MANF in Antibiotic Induced Ototoxicity: (actual number of licenses not mentioned, however, ototoxicity covers over 120 drugs and pharmacological agents)
http://medical-dictionary.thefreedictionary.com/ototoxicity
http://ir.amarantus.com/company-news/detail/1...totoxicity
*note: AMBS has several assays covering the same indications: two diagnostic for ALS, and a therapeutic as well..etc.
It appears to me that over the past two and a half years AMBS has been building a world class company with a massive pipeline. In that same time period they have gone from a company that only had office furniture, a gift of rented office space from the Michael J. fox Foundation (MJFF), and a portfolio with nothing more than MANF and the Phenogaurd cell lines; into a company worth ~50 million dollars and more than 138 assays in its pipeline, and other intellectual property as well.
It has come at the price of stock dilution, will there be future dilution?...yes, most certainly, but it will not be as severe as in the past, and the impact of future dilution will likely be offset by other funding sources. Perhaps by the Grow New Jersey tax credit, Grants from the DoD for ESS, The MJFF (Elto, Neuropro, MANF), or perhaps more favorable financing with the release of catalyst (GC said he has the CED data but cannot release it at this time).
I feel the future has tremendous potential for AMBS, so I hold long and strong!
Warmest regards,
Hoosier
This post should not be considered investment advise. I am not recommending to buy, sell, or hold this security, or any other. This post should be only considered my observations how AMBS has evolved over the past two and a half years.
GLTA
5
